Dyax Corporation

Genmab A+s

Baxter International Inc.

Baxter Healthcare Sa

Morphosys Ag

Baxalta Gmbh

Rene Hoet

Paul Parren

Robert Charles Ladner

Jan Van De Winkel

Edward Norbert Van Den Brink

Bart De Goeij

Janine Schuurman

Aran Frank Labrijn

Ole Baadsgaard

Henk Pieters

David Satijn

Clive R Wood

Daniel T Dransfield

Kristin L Rookey

Edward Hirsch Cohen

Horacio Gabriel Nastri

Simone De Haij

Thilo Riedl

Hendricus Renerus Jacobus Mattheus Hoogenboom

Laetitia Devy

Joyce Meesters

Joost J Neijssen

Simon E Hufton

Maria Henderikx

Sonia Schoonbroodt

Edward N Brink

Friedrich Scheiflinger

Tom Vink

Rob N De Jong

Randolf Kerschbaumer

Geert Mudde

Sandra Verploegen

Willem Karel Bleeker

David P E Satijn

Manfred Rieger

Michael Thiele

Eva Ehrnrooth

Maroeska Oudshoorn

Mischa Houtkamp

Vibeke Miller Breinholt

Nicholas Frans

Juergen Muellberg

Hendricus R Hoogenboom

Simone Haij

C Geert Mudde

Jürgen Muellberg

Robert C Ladner

Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Monoclonal antibodies against c-Met

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Monoclonal antibodies against HER2

Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.

Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries

Monoclonal antibodies against HER2 epitope

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Methods useful in constructing libraries that collectively display members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.

Methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins

Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Human antibodies against tissue factor and methods of use thereof

Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.

Method for treating breast cancer using antibody binding to MMP-14

Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods are disclose. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens are also disclosed.

The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.

Anti MIF antibodies

Growing community of inventors

Maastricht, Netherlands

Rene Hoet